Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin

Pediatr Neurol. 1995 Nov;13(4):336-9. doi: 10.1016/0887-8994(95)00195-6.


Two children with chronic dermatomyositis who were treated with intravenous immunoglobulin (IVIG) for 28 and 12 months, respectively, are reported. Both patients had received prednisone and immunosuppressive agents prior to IVIG treatments and had experienced significant side effects. Strength and functional abilities improved in both patients in a gradual stepwise fashion with IVIG treatment. One patient achieved remission and continues to do well without any immunosuppressive agents; in the other patient, the dose of oral steroids was reduced and other immunosuppressive agents were discontinued. Use of IVIG was associated with headaches, nausea, and vomiting in both patients. IVIG was an useful adjuvant therapy in these 2 children with dermatomyositis without any significant side effects.

Publication types

  • Case Reports

MeSH terms

  • Chemotherapy, Adjuvant
  • Child
  • Child, Preschool
  • Dermatomyositis / therapy*
  • Dose-Response Relationship, Drug
  • Humans
  • Immunoglobulins, Intravenous / adverse effects
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infusions, Intravenous
  • Male
  • Remission Induction


  • Immunoglobulins, Intravenous